Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Q4 2018 Earnings Conference Call - Final Transcript

Apr 02, 2019 • 08:30 am ET

Previous

Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Q4 2018 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Thank you for holding and welcome to the Titan Pharmaceuticals Fourth Quarter and Full-Year 2018 Financial Results Conference Call. At this time, all participants are in listen-only-mode. There will be a question-and-answer session following today's remarks. Please be advised that this call is being taped at the Company's request and will be archived on the Company's website starting later today.

At this time, I would like to turn the call over to Sunil Bhonsle, President and CEO of Titan Pharmaceuticals. Please go ahead.

Executive
Sunil Bhonsle

Thank you, Anita. And thank you all for joining us. Welcome to the Titan Pharmaceuticals call to review financial and operational results for the fourth quarter and year ended December 31, 2018. And we'll provide an update on our business. Before we begin, I wanted to inform you that we filed our 2018 annual report on Form 10-K yesterday with the SEC and amended it with a correction this morning.

And the press release issue provides a summary of the results and can be found on our website at titanpharm.com. Joining me on the call today from Titan are: Dr. Marc Rubin, our Executive Chairman; Dr. Kate Devarney, Executive Vice President and Chief Scientific Officer, Dane Hallberg, Executive Vice President and Chief Commercial Officer, and Brian Crowley, Vice President of Finance.

Before we go into the details of the financial results and provide an update on the Company, Jennifer Kiernan will review the required cautions regarding forward-looking statements.

Executive
Jennifer Kiernan

Thank you, Sunil.

I want to remind everyone that certain matters that will be discussed today other than historical information may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include but are not limited to any statements relating to our products commercialization and development programs, and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial conditions and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the commercialization of Probuphine, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters, and strategic agreements and relationships.

We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based except as required by law.

And now, back to you, Sunil.

Executive
Sunil Bhonsle

Thank you, Jennifer. Today, we will start the call with an overview from our Executive Chairman, Dr. Marc Rubin, followed by commercial updates from Dane Hallberg and regulatory updates from Dr. Kate DeVarney. Brian Crowley will then summarize the financial results and I will close with a brief recap before opening the call for your questions.

So we can get started. Marc?

Executive
Marc Rubin

Thank you, Sunil, and hello